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For my grandfather 
 
“Nothing in life is to be feared, it is only to be 
understood. Now is the time to understand more, so that 











Every three and a half minutes an individual dies from a stroke. Approximately 85% of 
strokes are ischemic, and over half of all ischemic strokes originate in the middle cerebral artery 
(MCA)1-2,6. Currently, standard stroke treatment includes intravenous infusion of recombinant 
tissue plasminogen activator (rTPA), a serine protease that’s primary function is to eliminate 
occlusion caused by blood clots via thrombolysis3. This method is only marginally effective at 
thrombolysis, cannot be reversed, and must be given within a timeframe of 3-4.5 hours of stroke 
onset, due to increased hemorrhage risk. Knowing that von Willebrand Factor (vWF), a known 
glycoprotein mediator in platelet adhesion and aggregation, plays a major role in vessel injury 
hemostasis, the Nimjee Lab developed a vWF-inhibiting aptamer, DTRI-031 (REF Oney, Nimjee 
et al. Oligonucleotides 2007; Nimjee et al. Molecular Therapy 2012 and Nimjee et al. Molecular 
Therapy 2019). Aptamers are RNA or DNA oligonucleotides which bind to and inhibit specific 
target molecules (REF Nimjee et al. Annual Reviews of Medicine 2005).  
In this study, we tested the hypothesis that DTRI-031 can lyse a blood clot 6 hours after it 
is placed in the MCA of canine hounds4. Furthermore, DTRI-031 can be rapidly reversed by 
another single-stranded RNA ligand, DTRI-025, to mitigate hemorrhage risk induced by the 
activity of DTRI-031. This study aims to demonstrate the efficacy of DTRI-031 to thrombolyse an 
occlusive thrombus in a large animal MCA occlusion (MCAO) model by measuring functional 
differences at different aptamer concentrations, like reperfusion rate, infarct volume, and inhibition 
of platelet activity and aggregation. Additionally, this study aims to demonstrate the reversibility 
of DTRI-031 by DTRI-025 using a point-of-care platelet activity assay (PFA-100) and platelet 
aggregometry. We anticipate that higher concentrations of DTRI-031 will result in improved 
cerebral perfusion, decreased infarct size, and lower platelet aggregation. Moreover, DTRI-025 
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A. Historical Background, Motivation, and Significance: 
 
According to the American Stroke Association (ASA) “Heart Disease and Stroke Statistics: 
2021 Edition”, approximately 920,000 Americans suffer a stroke annually. Of those, 795,000 are 
acute ischemic strokes. Approximately, 610,000 AIS are first-time strokes, and 185,000 are 
recurrent6. There are three main categories of stroke: acute ischemic stroke (AIS), intracerebral 
hemorrhagic stroke (ICH), and subarachnoid hemorrhagic stroke (SAH). Hemorrhagic strokes are 
defined by the rupture/tearing of blood vessels within the brain, leading to blood pooling inside 
the skull, whereas AIS presents via a blockage within the vessel itself, limiting oxygen to the brain. 
Looking again at the ASA “Heart Disease and Stroke Statistics: 2021 Edition”, of all strokes, 87% 
are AIS, 10% are ICH, and 3% are SAH6. 
Currently, the prevailing treatments for AIS include antiplatelet and thrombolytic therapy. 
Antiplatelet therapies work to stop platelets from sticking together and forming a clot through the 
use of drugs like low-dose aspirin. While these drugs can be helpful in clot prevention, they have 
the potential to cause side effects like gastrointestinal bleeding or hemorrhagic stroke7-9. 
Thrombolytic therapies, on the other hand, work to break apart (lyse) an existing blood platelet 
clot. Currently, the only FDA approved thrombolytic therapy for the treatment of ischemic stroke 
is rTPA, which is only given to approximately 8.5% of patients who present with AIS. 
Additionally, >66% of US hospitals rarely, or never, administer rTPA to AIS patients due to the 
small timeframe in which it can be given (<4.5 hours) and potential harmful side effects, such as 
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hemorrhaging, that can present after its administration to the patient10-11. These side effects can 
also include additional stroke onset in the form of hemorrhagic stroke due to the rTPA thinning 
the blood in the process of lysing the thrombus, with no reversibility12. As a result, there is a 
distinct lack of safe, and reversible, therapeutic options for both the early and long-term treatment 
of AIS patients 3-5. 
 
B. Platelet Aggregation and Coagulation: 
Understanding the basic concepts of blood clot formation is a crucial first step in 
developing a safe and effective treatment for Ischemic stroke. As such, it is important to take the 
time and understand the role that platelets have in blood clot formation, one of the smallest factors 
involved in the formation of a thrombus. Platelets are small anuclear cell fragments that are 
produced by megakaryocytes in the bone marrow13. Under hemostatic conditions, platelets will 
circulate within vasculature, but not stick to the endothelial surface of vessels for an extended 
period of time. Once a vascular injury occurs, the endothelial cell layer is compromised and the 
subendothelial extracellular matrix (ECM) becomes exposed, creating a highly thrombogenic 
environment for platelet adhesion. To return to hemostasis, platelets will adhere to the ECM at the 
injured site and form a hemostatic plug. This is largely accomplished via interaction of the platelet 
membrane receptor complex, Glycoprotein Ib-IX-V (GPIb-IX-V), and the A1 domain of a 
multimeric glycoprotein vWF. vWF is released by Weibel Palade bodies from the endothelial 
surface and from the alpha-granules of activated platelets, that together,  flood to the injured site12. 
Together with thrombin, a locally produced enzyme that is released at the injury site to increase 
platelet aggregation, more platelets are recruited to the injury site and self-adhere, a process known 
as aggregation13. As will be described in detail next, vWF plays a crucial role in this platelet-
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platelet aggregation during the formation of the hemostatic plug. This interaction is summarized 

















Figure 1: The interaction between Von Willebrand Factor (vWF) and glycoprotein Ib-IX-V (GPIb-
IX-V), modified from Varga-Szabo et al.  
 
 
C. The Role of vWF in Stroke: GPIb-IX-V - vWF Tethering: 
As previously defined, vWF is a multimeric glycoprotein involved in the formation of a 
hemostatic plug (thrombus) when a vascular injury occurs. Studies have demonstrated that 
incidence of AIS correlates with vWF levels among persons at risk15,16. The cascade of interactions 
that vWF is involved in for a hemostatic plug to form is explained here. First, exposed 
subendothelial ECM collagen at the site of injury interacts with circulating blood platelets via the 
glycoprotein Ib (GPIb) subunit of the GPIb-IX-V complex on the blood platelets surface. vWF 
serves as a tether between GPIb and the ECM collagen, and is critical for the initial slowing of 
flowing platelets17-20. Ex vivo studies of human blood have demonstrated that the GPIb-IX-V - 
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vWF interaction is the primary adhesive interaction in the initiation of blood platelet adhesion with 
shear rates >1000s-1 21. These high shear rates are most often found in small arteries, such as the 
MCA, which make it an attractive target for anti-thrombotic therapies21. Next, the glycoprotein 
IIb/IIIa (GPIIb/IIIa) complex is activated due to the initial interaction of GPIb-IX-V with vWF. 
GPIIb/IIIa activation transitions a “resting state” of integrin 2b3 to an “activated state” and is 
characterized by interactions of this integrin with other platelets via both fibrinogen and vWF, 
allowing for platelet-platelet aggregation/adhesion to occur. Finally, the initial interaction of  
GPIb-IX-V with vWF also activates the glycoprotein Ia/IIa (GPIa/IIa) complex, enabling 
integrin 21 to bind to the exposed collagen of the subendothelial ECM at the injured site as well. 
All three of these major interactions acting in unison are what produce the thrombus, inducing 
AIS; and all three stem from the initial interaction between GPIb and vWF (Figure 1., Figure 
2.)14,22. Keeping this process in mind, inhibitors of vWF have been shown to limit thrombosis,23-26 
however, one would expect their effect on hemostasis to lead to significant bleeding in the surgical 
setting25-27. Knowing this, it is clear as to why vWF is so important in the formation of a thrombus, 











Aptamers are RNA or DNA-based oligonucleotide molecules that function by folding into 
3-D structures, binding to and inhibiting the function of target proteins with high affinity and 
specificity4. While most antithrombotic therapeutics routinely come with the risk of hemorrhage 
due to lack of reversibility, antithrombotic aptamers are carefully regulated with a complementary 
antidote oligonucleotide, showing their potential to safely treat thrombosis. Additionally, 
Advantages to using aptamers as drug agents include the ability to modify their half-life, unlimited 
shelf life, low immunogenicity, and because their isolation occurs in vitro, aptamers can be 
functionally isolated to virtually any protein (REF Nimjee et al. annual Reviews of Medicine 2005).  
As previously described, vWF is a promising target for antithrombotic therapeutics as it 
plays a critical role in activating platelet adhesion, activation and aggregation by its initial binding 
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to the GPIb subunit of the GPIb-IX-V complex on the blood platelets surface. Thus, our 
laboratory has developed an RNA aptamer (DTRI-031) that binds to and inhibits vWF, as well as 
designed a specific reversal agent (DTRI-025) to regulate its activity. The combination of anti-
VWF aptamer DTRI-031 and specific neutralizing oligonucleotide DTRI-025 represents the first 
rationally-designed drug-antidote pair to treat thrombotic disease. 
 
E. Research Goals:  
As stated above, rTPA improves functional and neurological outcomes in AIS patients, but 
the risk of hemorrhage gives it a small timeframe in which it can be administered (<4.5 hours)10-
11. Thus, our goal was to develop a more robust treatment for AIS by targeting vWF, the major 
component of the thrombus seen in patients who suffer AIS (REF: DiMeglio et al. Neurology 
2019). By inhibiting vWF, DTRI-031 blocks the initial interaction of the platelet’s GPIb-IX-V 
complex with vWF. This initial inhibition not only prevents platelet adhesion and aggregation in 
thrombus formation on the exposed ECM of the vessel wall, but can also recanalize a vessel in 
which an already stable thrombus is present (REF Nimjee et al. Molecular Therapy 2019). 
Furthermore, by matching DTRI-031 with a specific reversal oligonucleotide DTRI-025, and 
determining optimum concentration of said antidote, (Figure 3) complete reversal of the aptamer 
can occur, providing a means to prevent devastating intracranial hemorrhaging from occurring 
and extending treatment time beyond the 4.5 hours that limits rTPA administration. By utilizing 
a clinically-relevant middle cerebral arterial occlusion (MCAO) stroke model and extending the 
duration of the stroke to 6 hours before administering treatment, we aimed to demonstrate that 













Figure 3: Antidote oligonucleotide (DTRI-025) binds to VWF aptamer (DTRI-031) by 
Watson Crick base pairing preventing it from binding to the target protein.  
 
 
III. Materials and Methods: 
A. Animals 
All experiments were approved by The Ohio State University Institutional Animal Care 
and Use Committee At The Ohio State University Interventional Cardiology Core, 32 adult 
hounds purchased from Covance Incorporated (24-45 kg, > 1 year of age) were used to evaluate 
VWF inhibition by DTRI-031 in a large animal of stroke (Table 1). Hounds (N = 32), were 
group housed in a temperature and humidity-controlled vivarium at Wiseman Hall and 
maintained by ULAR staff. Hounds were pre-medicated with intramuscular acepromazine 
followed by ketamine and midazolam, intubated, placed on a ventilator, and maintained with 
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continuous inhalation of isoflurane. Deep anesthesia was verified by loss of consciousness, loss 
of reflex or muscle response, and loss of response to stimuli.  
 
B. Middle Cerebral Arterial Occlusion (MCAO): 
 To perform MCAO, animals were positioned supine, with the right femoral artery and vein 
surgically exposed.  A 4-French sheath was placed into the artery for endovascular access, in order 
to place an occlusive thrombus and perform angiography.  A 4-French venous sheath was placed 
for drug administration, and a second 4-F arterial sheath for timed blood draws.  Baseline Platelet 
Function Analysis (PFA-100), whole blood impedance aggregometry (Chronolog), and buccal 
bleeding time data were all collected, with materials and methodology having been optimized for 
canine subjects29. An MCA stroke was induced by inserting a micro-catheter into the right MCA 
artery under fluoroscopic guidance using a GE 9900 Fluoroscope (GE Healthcare, Chicago, 
IL)30.  An autologous thrombus was then introduced that had been prepared as described35,36 and 
occlusion was verified angiographically.  Six hours after MCAO induction, DTRI-031 was 
administered over 5 minutes at 0.5. 1.0, or 5.0 mg/kg intravenously and whole blood was collected 
at designated times (Table 1/Table 2 below). This time point was chosen as it is outside the 
therapeutic limit for rTPA use. For Aptamer + Antidote experiments, ten minutes after the start of 
DTRI-031 infusion, DTRI-025 was administered at 0.5 mg/kg to assess DTRI-031 reversibility 
(Table 2), and whole blood was drawn again. DTRI-025 dosing was optimized in previous serial 
bleed experiments in canine blood. Magnetic resonance imaging (MRI) was performed 7 hours 
after MCAO. Animals were then sacrificed immediately thereafter, and necropsy was performed 
to isolate the heart, kidneys, liver, and brain for histopathologic evaluation. All procedures are in 
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routine use and were performed by the Interventional Cardiology Core, OSUWMC31. Canine 
experiments began October 10, 2020, and continued until April 9, 2021.  
 




Table 2. MCAO Study Timeline 
 
  
C. In Vivo Visualization of the Induced Thrombus 
Referring back to the basic concepts of platelet aggregation and blood clot formation 
described above and keeping in mind that the definition of AIS involves the blockage of an 
arterial pathway, cutting off vital nutrients (especially oxygen) to the brain, we made use of an 
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autologous clot35,36 via insertion through a 4-French sheath catheter into the Middle Cerebral 
Artery (MCA) of the Hounds. To verify both MCA occlusion and reperfusion after DTRI-031 
and DTRI-025 were given, digital subtraction angiography was performed on the hounds. This 
was done at baseline, after thrombus placement, and before sacrifice. The angiogram is an 
invaluable visualization tool as it utilizes a contrast agent at is delivered into the cranial arteries, 
making them visible on a fluoroscope (GE 9900) x-ray monitor, effectively creating a visual 
pathway of the cranial arteries (Figure 4). To classify percent revascularization of the MCA in 
hounds, the Thrombolysis in Cerebral Infarction (TICI) grading system was used. The TICI 
grading system allows for the determination of response to thrombolytic therapy after AIS. More 
specifically, the TICI method is broken down into four major grades (Grade 0, Grade 1, Grade 2, 
and Grade 3). Grade 2 also has two subclasses within its domain. All grades and subclasses are 
defined below in Table 3.37.   
Table 3. Definitions for Thrombolysis in Cerebral Infarction (TICI) Method. 
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A.                                           B.                                                     C.  
Figure 4. Use of fluoroscopic angiography allowed for verification of baseline MCA 
arterial flow (A.), followed by MCAO (B.), and finally reperfusion at sacrifice after 
DTRI-031infusion (C.) 
 
D. Quantification of Infarct Volume 
Brain MRI was performed immediately before sacrifice utilizing a Siemens Prisma 3 
Tesla MRI scanner (Siemens, Munich Germany). An ECG-gated breath-hold pulse sequence 
requiring a 10-15 second hold was used, depending on the animal’s heart rate. MRI capture 
protocol included single slice horizontal long axis (4 chamber view) steady-state free precision 
cine acquisition (8 mm slice thickness), multi-slice short axis cine acquisitions (8mm slice 
thickness, 0 mm separation), multi-slice short axis double inversion recovery fast spin echo 
imaging) and bright blood acquisitions (using steady state free precession imaging). For stroke- 
volume calculation from 2D images, we converted raw MRI images to DICOM format, 
importing them into Image J software. Most importantly, by delineating both whole brain and 
injured brain borders, we were able to quantify whole brain and infarct areas (Figure 5). Infarct 
regions were determined by outlining the affected region and verified in TTC staining (explained 
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next). Hound MRI was performed at The Ohio State University Center for Cognitive and 
Behavioral Brain Imaging (CCBBI). 
 
Figure 5. T2 Weighted MRI imaging allowed for quantification of infarct volumes 
following MCAO 
 
E. TTC Verification of Infarct Volumes and Reperfusion of Vessels  
We verified infarction and hemorrhage volumes, found on MRI, on a macro scale by 
obtaining consecutive coronal sections of hound brain and staining with triphenyl-2,3,5-
tetrazolium-chloride (TTC) to differentiate between metabolically active (red) and inactive 
(white) cells (Figure 6). TTC staining was performed by the Pathology Core at The Ohio State 




Figure 6. TTC stained (front and back) coronal brain section of hound (red is alive, 
white is dead) 
 
F. Platelet Reactivity Tests: Platelet Function Analysis (PFA), Chrono-log 
Aggregometry, and Buccal Mucosa Bleeding Time 
Verifying platelet reactivity as a result of DTRI-031 administration and DTRI-025 
neutralization was evaluated to ensure the safety and efficacy of the aptamer. To do this, platelet 
function analysis (PFA) was utilized to determine how well the subjects’ platelets were 
aggregating. The platelet function analyzer 100 (PFA-100) is a bench-top automated point-of-
care instrument that assesses primary hemostasis under shear stress. The PFA-100 uses a 
disposable test cartridge that contains a membrane impregnated with collagen plus ADP 
(Col/ADP membrane) or epinephrine (Col/Epi membrane)38. Whole Blood Impedance 
Aggregometry (WBIA) (Chrono-log) was used to verify how well the subjects’ platelets were 
aggregating once subjected to administered agonists. WBIA measures the change in electrical 
impedance between two electrodes when platelet aggregation is induced by an agonist. The 
method is performed using whole blood and so eliminates the need to generate platelet rich 
plasma [PRP]39. Optimal concentrations of agonists were used and included Collagen, ADP, and 
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Botrocetin. Lastly, Buccal Mucosa Bleeding Time (BMBT) was collected to determine the time 
required for clotting on the endothelium of the site of injury to occur in vivo. BMBT was 
performed by activating the Accriva Diagnostics Surgicutt™ Bleeding Time Device (Accriva 
Diagnostics  SU50I)40 at dimensions of 0.1 cm depth x 0.5 cm length on the endothelium of the 
animal, and timing the resulting bleeding until clotting had finished. All three of these platelet 
function analyses are based on the basic concepts we described in our introduction; that injury to 
the subendothelial ECM of the vessel triggers the initial activation of the GPIb-IX-V complex’s 
GPIb subunit with vWF, which results in a cascade of clotting events, leading to thrombus 
formation and subsequent AIS. 
G. Data Analysis 
Statistical analysis of collected data was performed via the software programs GraphPad 
Prism and Excel. and expressed as mean ± standard deviations. For comparison between two 
groups, significance will be determined by paired or unpaired Student t test. For comparison of 
multiple groups, multifactorial ANOVA with post hoc comparison will determine significance. 
For all data analysis, probability values of p < 0.05 were considered significant. See Table 1 for 







A. In Preliminary Data DTRI-031 Administration demonstrated overall reduced 
infarct volume 
After thrombus stabilization was verified, a 6-hour timer was started to allow the stroke 
to develop, after which time DTRI-031 was administrated. Scheduled angiography and blood 
draws were performed 10 minutes and 1 hour after DTRI-031 administration.  The animals were 
then transported for brain MRI utilizing a Siemens Prisma 3 Tesla MRI scanner (Siemens, 
Munich Germany). As stated above, an ECG-gated breath-hold pulse sequence requiring a 10-15 
second hold was used, depending on the animal’s heart rate. MRI of hounds treated with 
negative (Platelet Binding Buffer (PBB+)) control 6 hours after MCAO developed an infarct 47.0 
+/- 6.7% (N = 7). Overall, animals treated with DTRI-031 developed an infarct 44.2 +/- 15.5% 
(N = 8). Animals treated with DTRI-031 resulted in revascularization in 5 of 8 hounds (62.5%). 
The infarct volumes of animals that underwent DTRI-031-mediated revascularization was 29.3 
+/- 9,4%, which was significantly less than the negative control group (p<0.5, utilizing an 
unpaired t-test) (Figure 7.  
 
Figure 7.  DTRI-031-mediated recanalization reduces infarct volume 
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B. DTRI-031 Administration inhibited platelet reactivity  
In addition to reduced infarct volume, administration of DTRI-031 demonstrated 
inhibition of platelet reactivity. BMBT, PFA, WBIA were the three parameters we used for 
testing platelet reactivity to DTRI-031 and DTRI-025. For BMBT, our results indicated that 
DTRI-031 at concentrations of 5.0mg/kg and 1.0 mg/kg demonstrated the most efficacious 
platelet inhibition times. Specifically, 1.0 mg/kg showed a longer overall clotting time, but 5.0 
mg/kg held clotting time more steadily for a longer period of time. When DTRI-025 was 
administered after DTRI-031, durable aptamer reversal was witnessed with clotting times 
returning to normal in as little as 10 minutes (Figure 8). PFA showed similar results with DTRI-
031 concentrations of 5.0 mg/kg and 1.0 mg/kg presenting the longest closure time in response to 
aggregation. Again, 5.0 mg/kg held a steady closure time for the longest period of all tested 
concentrations (300 seconds for approximately 175 minutes) before inhibition began to diminish. 
Similarly, DTRI-025 quickly and durably reversed aptamer inhibition in as little as 10 minutes 
(Figure 9). Lastly, WBIA had similar results to both BMBT and PFA with DTRI-031 
concentrations of 5.0 mg/kg and 1.0 mg/kg showing the lowest overall impedance values, 
indicating the greatest inhibition of platelet reactivity. Just as was seen for DTRI-025 in the other 
two testing parameters, durable reversal of the aptamer occurred with impedance values 
returning to normal in as little as 10 minutes, indicating reversal of platelet inhibition (Figure 
10). (all other WBIA graphs can be found in the appendix). Note, all graphs start at 400 minutes 
as this was the time in which testing began relative to the experiment start time. Agreement 
among all three platelet reactivity testing parameters demonstrates consistency in the ability of 
DTRI-031 to inhibit platelet reactivity and in DTRI-025 to rapidly, and durably, reverse that 
inhibition.  
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Figure 8. MCAO Hound Buccal Mucosa Bleeding Time 
 
 
Figure 9. MCAO Hound PFA Closure Time 
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Figure 10. MCAO Hound Whole Blood Impedance Aggregometry Area-Under-the-Curve 
(AUC) for 1ug/ul Botrocetin Agonist Addition 
 
C. DTRI-031 Resulted in Increased Reperfusion of the MCA Compared to Control 
DTRI-031 recanalized the hound MCA after 6 hours of LVO stroke in 5 out of 8 dogs 
(62.5%), compared to no reperfusion in PBB+ (Saline) control (Figure 11). Digital subtraction 
angiography (DSA) was taken 1 hour after treatment and demonstrated no revascularization (a 
TICI grade of 0) in control (N = 7) as compared to DTRI-031 treatment, which resulted in  a 
TICI  grade of 2A in 12.5%,  2B in 37.5%, and all the way to a grade 3 in 12.5% of cases (N = 
8). These results demonstrate the ability of DTRI-031 to effectively lyse thrombi in vivo.  
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Figure 11. TICI-Based Reperfusion Percentages of MCAO Hounds 
 
D. DTRI-031/DTRI-025 Administration did not alter Canine Physiological Parameters: 
Administration of DTRI-031, and its subsequent neutralization with administration of DTRI-025) 
demonstrated no negative effects on animal physiology. Vital signs (Heart Rate, Mean Arterial 
Pressure, Mean Systolic Pressure, and Mean Diastolic pressure) were recorded throughout the 
entirety of the experiment, in order to ensure normal physiological conditions were maintained 
within the animal. Additionally, White Blood Cell counts and Platelet Counts (WBC, PC) were 
taken at baseline and before sacrifice, also to ensure normal physiological conditions were 
maintained within the animal. No significant difference was found in the mean blood pressures or 
heart rates between treatment groups. Normal increase in WBC count was seen and overall PC 
was maintained for all groups (DTRI-031 5.0mg/kg did not undergo WBC/PC counts due to 
logistical issues). All treatment groups resulted in normal physiological conditions during the 
entire surgical procedure (Figures 12.-17).  
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Figure 12. Mean Arterial Pressure at Timepoints (By Treatment) in MCAO Hounds 
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Figure 13. Mean Systolic Blood Pressure at Timepoints (By Treatment) in MCAO Hounds 
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Figure 14. Mean Diastolic Blood Pressure at Timepoints (By Treatment) in MCAO Hounds 
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Figure 16. WBC Count at Timepoints (By Treatment) for MCAO Hounds 
 
 




Acute Ischemic Stroke is at the forefront of translational medicine research because of 
the high prevalence, morbidity and mortality of the disease. Furthermore, over 85% of strokes 
are ischemic, and over half of all ischemic strokes originate in the Middle Cerebral Artery 
(MCA)1-2,6. Currently, standard stroke treatment includes intravenous infusion of recombinant 
tissue plasminogen activator (rTPA), a serine protease that’s primary function is to eliminate 
occlusion caused by blood clots via thrombolysis3. This method is only marginally effective at 
thrombolysis, but also cannot be reversed, and must be given within a timeframe of 3-4.5 hours 
of stroke onset, due to increased risk of hemorrhage into the brain. Potential replacement stroke 
therapies have been researched in the pre-clinical setting, but only a few have been effective 
when applied to the clinical setting33. von Willebrand Factor (vWF), a known glycoprotein 
mediator in platelet adhesion and aggregation, plays a major role in vessel injury hemostasis, is 
an optimal target for inhibition to treat 
 As was described in the introduction, vWF is a main contributor to both platelet 
activation and aggregation at the site of injury: First, exposed subendothelial ECM collagen at 
the site of injury interacts with circulating blood platelets with vWF serving as a tether between 
the GPIb-IX-V complex on the platelet and the ECM collagen. This step is critical for the initial 
slowing of flowing platelets.17-20   Next, the GPIIb/IIIa complex on the platelet is activated due to 
the initial interaction of GPIb-IX-V with vWF, allowing for platelet-platelet 
aggregation/adhesion to occur. Finally, the initial interaction of GPIb-IX-V with vWF also 
activates the GPIa/IIa complex, enabling further platelet binding to the exposed collagen at the 
injured site as well. All three of these major interactions acting in unison are what produce the 
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thrombus, inducing AIS; and all three stem from the initial interaction between the platelet and 
vWF (Figures 1 and 2)14,22.  
In past studies, DTRI-031 has shown efficacy in its ability to inhibit VWF and perform in 
vivo as an anti-platelet agent, preventing thrombus formation34. In this study we aimed to 
investigate the thrombolytic efficacy of DTRI-031. Utilizing clinically relevant stroke models 
with hounds, Acute Ischemic Stroke was demonstrated by occluding the middle cerebral artery 
of hounds and allowing a stroke to propagate for 6 hours after occlusion. The thrombolytic 
efficacy of DTRI-031 was then tested and compared to (PBB+) (saline) control. Our findings 
showed that DTRI-031 resulted in smaller infarct size than PBB+ control (Figure 7) with 0.5 
mg/kg, which in turn, resulted in the smallest infarct size and greater overall reperfusion (Figure 
11). Additionally, DTRI-031 administration resulted in longer platelet clotting times in vivo 
(Figure 8), longer time for blood flow to stop when aggravated ex vivo (reported as closure 
times) (Figure 9), and lower overall impedance when platelets were subjected to agonists ex 
vivo, suggesting less platelet-platelet activation (Figure 10). All three of these platelet activity 
testing parameters showed inhibition of the basic GPIb-IX-V platelet complex-vWF interactions 
that were described in the introduction. This inhibition is what prevents the cascade of clotting 
events that result in thrombus formation and AIS. Finally, no adverse effects to hound baseline 
physiology were found (Figures 12-17). 
The results presented in this study demonstrate the ability of DTRI-031 to inhibit vWF 
effectively, and highlight its role as a thrombolytic agent in a large animal model of 
thromboembolic stroke. This is an ongoing study, and our team believes that with further 
investigation, DTRI-031 inhibition of vWF can provide a treatment option other than rTPA for 
those 91.5% of stroke patients who cannot receive rTPA and are left with little options for acute 
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therapy. Furthermore, we believe that pairing DTRI-031 with its complementary reversal agent, 
DTRI-025, will provide a measure of defense to mitigate the hemorrhaging side effects that 
currently plague stroke treatment. Potential future applications could be administration of the 
DTRI-031 in veno-occlusive disease such as deep vein thrombosis and pulmonary embolus, as 
well as possibly loading the drug on a stent, which could be used as a preventative measure in 
potential at-risk stroke patients.  
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